bio personality
KIRAN MAZUMDAR SHAW
CONFERRED HIGHEST FRENCH CIVIL
DISTINCTION
The highest French civil distinction,
Chevalier de la L gion d Honneur
DR KURT STOECKLI IS THE NEW
PRESIDENT & CSO OF GLENMARK
Glenmark has announced the
appointment of Dr Kurt Stoeckli as
President and Chief Scientific Officer
(CSO). Dr Stoeckli joins Glenmark from
SANOFI where he was Group Vice
President, Global Biopharmaceuticals
Division & Chief Scientific Officer for
R&D France.
PARAS HEALTHCARE APPOINTS DR
SHANKAR NARANG AS COO
Leading specialty hospital chain,
Paras Healthcare has announced a
major management expansion, with
the appointment of healthcare
He will report to Glenn Saldanha,
Chairman and MD and will be based
out of Neuchâtel, Switzerland. He will
also be President and General Manager
of Glenmark's Switzerland-based
business units.
(Knight of the Legion of Honour) was
conferred on Biocon Chairperson and
MD Kiran Mazumdar-Shaw by
French Ambassador Alexandre
Ziegler on behalf of the President of
the French Republic.
The honour comes in recognition of
her outstanding contribution and
dedication to the Biosciences and
innovative research in this field.
Dr Stoeckli will lead the company's
global research portfolio consisting of
NBE, NCE, generics and branded
formulations. He will be responsible for
sustaining and enhancing the
environment of collaborative research
and for driving successful
commercialization of Glenmark'
research pipeline in partnership with
other leaders.
It also for her achievements in
biotechnology and commitment to
providing affordable, quality
healthcare globally.
Speaking on the occasion, Ziegler
said, "It is immense pleasure and
honour for me to host the investure
ceremony to confer the L gion d
Honneur on Ms Kiran MazumdarShaw, a pioneering entrepreneur in
biotechnology and research." By
providing innovative and affordable
treatment for widespread diseases
like diabetes, cancer, and autoimmune diseases, she has made a
laudable difference to the lives of
many, he added.
"It is a proud privilege for me to be
bestowed the Chevalier de la L gion d
Honneur by the Government of
France. To be recogonised by one's
own country is a matter to honour,
but to receive recognition by another
country is indeed a very special
honour. I am deeply grateful and
humbled by the French," MazumdarShaw said while accepting the award.
"We are pleased to bring Dr. Stoeckli's
expertise to Glenmark which will
further drive the advancement of our
new molecular entity portfolio and
enable us to continue discovering
NMEs both small molecules and
biologics," said Glenn Saldanha,
Chairman and MD, Glenmark
Pharmaceuticals Ltd.
Having spent more than two decades in
the pharmaceutical industry, Dr.
Stoeckli has an extensive industry
experience in driving biologics from
early research up to phase 3. He has
played a pivotal role in fostering and
managing Sanofi's JV with Regeneron
Pharmaceuticals Inc.
operations veteran Dr Shankar
Narang as the Chief Operating Officer
of the Group, which has ambitious
plans of expanding its presence
across North India over the next
three years.
Dr Shankar brings with him more
than 15 years of extensive experience
in healthcare and operational
delivery having been associated with
several organizations of repute
including Fortis and Max Healthcare,
to name a few. He has earlier also
worked with Paras Hospitals as GM
Operations & Quality for five years
and has a fair understanding of
the Group’s organizational ethics
and culture.
As COO, he will be responsible for
overseeing operations at all hospitals
and healthcare verticals of Paras
Group including Paras Hospitals (the
chain of multi super specialty
hospitals), Paras Bliss (chain of
mother and child care hospitals) and
Paras Cancer Centre (chain of
specialized cancer care centres).
Group MD, Dr Dharminder Nagar
said, “As we set on major plans for
expanding our presence across North
India, we need to strengthen our
leadership to enable Paras Healthcare
bridge the healthcare gap and become
community healthcare providers that
deliver specialized medical expertise
based on affordability, accessibility
and quality.”
BIOVOICENEWS.COM
13